Area | Parameter | Comparison | Overall effect | Heterogeneity | ||
Mean difference (95% CI) | P value | I² test (%) | Q test (P) | |||
PRNFL | Overall | HC versus non-DON | −1.51 (−4.30 to 1.28) | 0.29 | 73 | 0.005 |
HC versus DON | −3.90 (−13.22 to 5.43) | 0.41 | 96 | 0.00 | ||
non-DON versus DON | −7.06 (−20.52 to 6.41) | 0.30 | 97 | 0.00 | ||
Superior-hemi | HC versus non-DON | −0.62 (−5.28 to 4.03) | 0.79 | 72 | 0.06 | |
HC versus DON | 7.66 (−7.23 to 22.55) | 0.31 | 83 | 0.02 | ||
non-DON versus DON | 3.84 (−9.14 to 16.81) | 0.56 | 80 | 0.006 | ||
Inferior-hemi | HC versus non-DON | −4.03 (−11.25 to 3.19) | 0.27 | 89 | 0.002 | |
HC versus DON | 2.64 (−12.20 to 17.48) | 0.73 | 87 | 0.006 | ||
non-DON versus DON | 1.93 (−9.93 to 13.79) | 0.75 | 85 | 0.001 | ||
S | HC versus non-DON | −3.21 (−11.79 to 5.36) | 0.46 | 84 | 0.007 | |
HC versus DON | −11.78 (−31.11 to 7.55) | 0.23 | 94 | 0.00 | ||
non-DON versus DON | −21.96 (−63.83 to 19.90) | 0.30 | 97 | 0.00 | ||
T | HC versus non-DON | −2.72 (−7.30 to 1.86) | 0.24 | 55 | 0.11 | |
HC versus DON | −0.42 (−6.35 to 5.51) | 0.89 | 77 | 0.002 | ||
non-DON versus DON | −1.83 (−11.83 to 8.16) | 0.72 | 70 | 0.03 | ||
I | HC versus non-DON | −4.27 (−11.21 to 2.67) | 0.23 | 62 | 0.07 | |
HC versus DON | −11.73 (−30.35 to 6.90) | 0.22 | 94 | 0.00 | ||
non-DON versus DON | −21.48 (−65.23 to 22.26) | 0.34 | 97 | 0.00 | ||
N | HC versus non-DON | −1.57 (−11.18 to 8.03) | 0.75 | 88 | 0.00 | |
HC versus DON | −8.04 (−22.15 to 6.08) | 0.26 | 96 | 0.00 | ||
non-DON versus DON | −13.71 (−48.21 to 20.79) | 0.44 | 98 | 0.39 | ||
MGCCL | Overall | HC versus non-DON | 0.29 (−0.39 to 0.97) | 0.41 | 69 | 0.01 |
HC versus DON | −3.15 (−3.74 to −2.56) | 0.00 | 87 | 0.00 | ||
non-DON versus DON | −7.27 (−10.80 to −3.74) | 0.00 | 76 | 0.00 | ||
Superior-hemi | HC versus non-DON | 0.02 (−0.75 to 0.80) | 0.95 | 70 | 0.07 | |
HC versus DON | −3.38 (−4.09 to −2.66) | 0.00 | 92 | 0.00 | ||
non-DON versus DON | −7.30 (−12.84 to −1.76) | 0.01 | 79 | 0.00 | ||
Inferior-hemi | HC versus non-DON | 1.07 (0.26 to 1.87) | 0.009 | 73 | 0.06 | |
HC versus DON | −2.22 (−2.77 to −1.68) | 0.00 | 95 | 0.00 | ||
non-DON versus DON | −9.07 (−16.56 to −1.59) | 0.02 | 88 | 0.00 | ||
GCL+IPL | Overall | HC versus non-DON | −4.42 (−5.81 to −3.03) | 0.00 | 0 | 057 |
HC versus DON | −9.41 (−11.76 to −7.06) | 0.00 | 0 | 0.70 | ||
non-DON versus DON | −4.95 (−7.42 to −2.48) | 0.00 | 0 | 0.46 |
DON, dysthyroid optic neuropathy; GCL+IPL, ganglion cell layer and inner plexiform layer; HC, healthy control; I, inferior; Inferior-hemi, inferior hemifield; MGCCL, macular ganglion cell complex layer; N, nasal; non-DON, thyroid-associated ophthalmopathy without DON; OCT, optical coherence tomography; PRNFL, peripapillary retinal nerve fibre layer; S, superior; Superior-hemi, superior hemifield; T, temporal.